Emergency presentations of Parkinson's disease: Early recognition and treatment are crucial for optimum outcome

Postgraduate Medical Journal

Volumn 87, Issue 1024, 2011, Pages 125-131

  Ghosh, R ^a   Liddle, B J ^a  

^a NORTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; CLOZAPINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; QUETIAPINE;

DYSPHAGIA; EARLY DIAGNOSIS; FALLING; FATALITY; HUMAN; MORTALITY; MOTOR DYSFUNCTION; NEUROLEPTIC MALIGNANT SYNDROME; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PATHOPHYSIOLOGY; PSYCHOSIS; REVIEW; SEROTONIN SYNDROME; SYMPTOM; TREATMENT PLANNING;

EARLY DIAGNOSIS; EMERGENCY TREATMENT; HUMANS; PARKINSON DISEASE; TIME FACTORS; TREATMENT OUTCOME;

EID: 79951554216     PISSN: 00325473     EISSN: 14690756     Source Type: Journal    
DOI: 10.1136/pgmj.2010.104976     Document Type: Review

References (86)

1. Zhang Z, Roman G. Worldwide occurrence of Parkinson's disease: an updated review. Neuroepidemiology 1993;12:195-208. (Pubitemid 23353338)
2. Schrag A, Ben-Sholmo Y, Quinn NP. Cross sectional prevalence survey of idiopathic Parkinson's disease and Parkinsonism in London BMJ 2000;321:21.
3. The National Institute for Health and Clinical Excellence. Parkinson's disease: diagnosis and management in primary and secondary care. 2006. http://www.nice. org.uk/CG035 (accessed 28 Aug 2010).
4. Parashos SA, Maraganore DM, O'Brien PC, et al. Medical services utilization and prognosis in Parkinson's disease: a population-based study. Mayo Clin Proc 2002;77:918-25. (Pubitemid 34977634)
5. Woodford H, Walker R. Emergency hospital admissions in idiopathic Parkinson's disease. Mov Disord 2005;20:1104-8. (Pubitemid 41632195)
6. Koller WC, Glatt S, Vetere-Overfield B, et al. Falls and Parkinson's disease. Clin Neuropharmacol 1989;12:98-105. (Pubitemid 19088635)
7. Wood BH, Bilclough JA, Walker RW. Incidence and prediction of falls in Parkinson's disease: a prospective multidisciplinary study. J Neurol Neurosurg Psychiatry 2002;72:721-5. (Pubitemid 34557012)
8. Wielinski CL, Erickson Davis C, Wichmann R, et al. Falls and injuries resulting from falls among patients with Parkinson's disease and other Parkinsonian syndromes. Mov Disord 2005;20:410-15. (Pubitemid 40779015)
9. Dunn JE, Rudberg MA, Furner SE, et al. Mortality, disability, and falls in older persons: the role of underlying disease and disability. Am J Public Health 1992;82:395-400.
10. Kiel DP, O'Sullivan P, Teno JM, et al. Health care utilization and functional status in the aged following a fall. Med Care 1991;29:221-8.
11. Johnell O, Melton LJ III, Atkinson EF, et al. Fracture risk in patients with Parkinsonism: a population based study in Olmsted County, Minnesota. Age Ageing 1992;21:32-8.
12. Genever RW, Downes TW, Medcalf P. Fracture rates in Parkinson's disease compared with age and gender-matched controls: a retrospective cohort study. Age Ageing 2005;34:21-4. (Pubitemid 40109663)
13. Todd CJ, Freeman CJ, Camilleri-Ferrante C, et al. Differences in mortality after fracture of hip: the east anglian audit. BMJ 1995;310:904-8.
14. Keene GS, Parker MJ, Pryor GA. Mortality and morbidity after hip fractures. BMJ 1993;307:1248-50.
15. Boereboom FT, Raymakers JA, Duursma SA. Mortality and causes of death after hip fractures in the Netherlands. Neth J Med 1992;41:4-10.
16. Clubb VJ, Clubb SE, Buckley S. Parkinson's disease patients who fracture their neck of femur: a review of outcome data. Injury 2006;37:929-34. (Pubitemid 44311120)
17. Allcock LM, Ullyart K, Kenny R, et al. Frequency of orthostatic hypotension in a community acquired cohort of patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 2003;75:1470-1.
18. Montastruc JL, Chamontin B, Senard JM, et al. Domperidone in the management of orthostatic hypotension. Clin Neuropharmacol 1985;8:191-2. (Pubitemid 15055817)
19. Schoffer KL, Henderson RD, O'Maley K, et al. Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson's disease. Mov Disord 2007;22:1543-9. (Pubitemid 47477913)
20. Merello M, Pirtosek Z, Bishop S, et al. Cardiovascular reflexes in Parkinson's disease: effect of domperidone and apomorphine. Clin Auton Res 1992;2:215-19.
21. Nilsson H, Ekberg O, Olsson R, et al. Quantitative assessment of oral and pharyngeal function in Parkinson's disease. Dysphagia 1996;11:144-50. (Pubitemid 26107517)
22. Edwards LL, Quigley EM, Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease: frequency and pathophysiology. Neurology 1992;42:726-32.
23. Miller N, Noble E, Jones D, et al. Hard to swallow: dysphagia in Parkinson's disease. Age Ageing 2006;35:614-18. (Pubitemid 44614157)
24. Hoehn M, Yahr M. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-42.
25. Calon F, Tahar AH, Blanchet PJ, et al. Dopamine receptor stimulation: behavioural and biochemical consequences. Trends Neurosci 2000;23:S92-100.
26. Thanvi B, Lo N, Robinson T. Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment. Postgrad Med J 2007;83:384-8. (Pubitemid 46960824)
27. Marsden CD, Parkes JD, Quinn N. Fluctuations of disability in Parkinson's disease: clinical aspects. In: Marsden CD, Fahn S, eds. Movement Disorders. London: Butterworth Scientific, 1982:96-122.
28. Kaakkola S, Teräväinen H, Ahtila S, et al. Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in Parkinsonian patients. Neurology 1994;44:77.
29. Chatzizisis Y, Misirli G, Hatzitolios AI, et al. The syndrome of rhabdomyolysis: complications and treatment. Eur J Intern Med 2008;19:568-74.
30. Pappert EJ, Goetz CG, Niederman F, et al. Liquid levodopa/carbidopa produces significant improvement in motor function without dyskinesia exacerbation. Neurology 1996;47:1493-5. (Pubitemid 26422542)
31. Katzenschlager R, Hughes A, Evans A, et al. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges. Mov Disord 2005;20:151-7. (Pubitemid 40361117)
32. Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 2006;5:677-87. (Pubitemid 44081890)
33. Chase TN. Levodopa therapy: consequences of the nonphysiologic replacement of dopamine. Neurology 1998;50:S17-25.
34. Shoulson I, Glaubiger GA, Chase TN. On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in Parkinsonian patients. Neurology 1975;25:1144-8.
35. Quinn N, Marsden CD, Parkes JD. Complicated response fluctuations in Parkinson's disease: response to intravenous infusion of levodopa. Lancet 1982;2:412-15. (Pubitemid 12039838)
36. Quinn N, Parkes JD, Marsden CD. Control of on/off phenomenon by continuous intravenous infusion of levodopa. Neurology 1984;34:1131-6. (Pubitemid 14068582)
37. Antonini A, Isaias IU, Canesi M, et al. Oral and infusion levodopa-based strategies for managing motor complications in patients with Parkinson's disease. CNS Drugs 2010;24:119-29.
38. Nyholm D, Nilsson Remahl AI, Dizdar N, et al. Comparison of apomorphine and levodopa infusions in four patients with Parkinson's disease with symptom fluctuations. Acta Neurol Scand 2008;119:345-8.
39. Sydow O. Parkinson's disease: recent development in therapies for advanced disease with a focus on deep brain stimulation (DBS) and duodenal levodopa infusion. FEBS J 2008;275:1370-6. (Pubitemid 351388784)
40. Nyholm D. Duodopa: history and facts. Acta Neurol Scand 2008;117:68.
41. Iranzo A. Sleep and breathing in multiple system atrophy. Curr Treat Options Neurol 2007;9:347-53. (Pubitemid 47377236)
42. Archibald N, Newman P. Recurrent choking in Parkinson's disease. Pract Neurol 2009;9:110-13.
43. Fikkers BF, Zandstra DF. Primary laryngospasm in a patient with Parkinson's disease: treatment with CPAP via minitracheostomy following intubation. Intensive Care Med 1995;21:863-4.
44. Iranzo A, Santamaria J, Tolosa E. Continuous positive air pressure eliminates nocturnal stridor in multiple system atrophy. Barcelona Multiple System Atrophy Study Group. Lancet 2000;356:1329-30.
45. Graham JM, Grünewald RA, Sagar HJ. Hallucinosis in idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1997;63:434-40. (Pubitemid 27423547)
46. Lopez-Meza E, Ruiz-Chow A, Ramirez-Bermudez J. Aripiprazole in psychosis associated with Parkinson's disease. J Neuropsychiatry Clin Neurosci 2005;17:421-2. (Pubitemid 46179308)
47. Fenelon G, Machieux F, Huon R, et al. Hallucinations in Parkinson's disease, prevalence, phenomenology and risk factors. Brain 2000;123:733-45. (Pubitemid 30162723)
48. Holroyd S, Currie L, Wooten GF. Prospective study of hallucinations and delusions in Parkinson's disease. J Neurol Neurosurg Psychiatry 2001;70:734-8. (Pubitemid 32554202)
49. George J, Bleasdale S, Singleton SJ. Causes and prognosis of delirium in elderly patients admitted to a district general hospital. Age Ageing 1991;20:332-6.
50. Factor SA, Feustel PJ, Friedman JH, et al. Longitudinal outcome of Parkinson's disease patients with psychosis. Neurology 2003;60:1756-61. (Pubitemid 36737069)
51. British Geriatrics Society. An abstract of the Guidelines for the prevention, diagnosis and management of delirium in older people in hospital, published January 2006. http://www.bgs.org.uk/Publications/ Clinical%20Guidelines/clinical-1-2-delirium.htm (accessed 4 Feb 2010).
52. Quinn N. Drug treatment of Parkinson's disease. BMJ 1995;310:575-9.
53. Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med 1999;340:757-63.
54. Pfeiffer C, Wagner ML. Clozapine therapy for Parkinson's disease and other movement disorders. Am J Hosp Pharm 1994;51:3047-53.
55. Merims D, Balas M, Peretz C, et al. Rater - blinded prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis. Clin Neuropharmacol 2006;29:331-7. (Pubitemid 44729944)
56. Pollak P, Tison F, Rascol O, et al. Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry 2004;75:689-95. (Pubitemid 38526677)
57. Rabey JM, Prokhorov T, Miniovitz A, et al. Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labelled study of 3 months' duration. Mov Disord 2007;22:313-18. (Pubitemid 46569682)
58. Ondo WG, Tintner R, Voung KD, et al. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Mov Disord 2005;20:958-63. (Pubitemid 41419510)
59. Parsa MA, Bastani B. Quetiapine (seroquel) in the treatment of psychosis in patients with Parkinson's disease. J Neuropsychiatry Clin Neurosci 1998;10:216-19. (Pubitemid 28241371)
60. Morgante L, Epifanio A, Spina E, et al. Quetiapine and clozapine in Parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol 2004;27:153-6. (Pubitemid 39121725)
61. Weintraub D, Howard I, Hurtig MD. Presentation and management of psychosis in Parkinson's disease and dementia with lewy bodies. Am J Psychiatry 2007;164:1491-8. (Pubitemid 350069725)
62. Frieling H, Hillemacher T, Ziegenbein M, et al. Treating dopamimetic psychosis in Parkinson's disease: structured review and meta-analysis. Eur Neuropsychopharmacol 2007;17:165-71. (Pubitemid 44779199)
63. Zhong KX, Sweitzer DE, Hamer RM, et al. Comparison of quetiapine and risperidone in the treatment of schizophrenia: a randomized, double-blind, flexible-dose, 8-week study. J Clin Psychiatry 2006;67:1093-103. (Pubitemid 44230881)
64. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004;351:2509-18. (Pubitemid 39603164)
65. Kim JH, Kwon TH, Koh SB, et al. Parkinsonism-hyperpyrexia syndrome after deep brain stimulation surgery: case report. Neurosurgery 2010;66:1029.
66. Gordon PH, Frucht SJ. Neuroleptic malignant syndrome in advanced Parkinson's disease. Mov Disord 2001;16:960-2. (Pubitemid 36041203)
67. Keyser DL, Rodnitzky RL. Neuroleptic malignant syndrome in Parkinson's disease after withdrawal or alteration of dopaminergic therapy. Arch Intern Med 1991;151:794-6.
68. Granner MA, Wooton GF. Neuroleptic malignant syndrome or Parkinson hyperpyrexia syndrome. Semin Neurol 1991;11:228-35.
69. Toru M, Matsuda O, Makiguchi K, et al. Neuroleptic malignant syndrome-like state following a withdrawal of antiparkinsonian drugs. J Nerv Ment Dis 1981;169:324-7. (Pubitemid 11107633)
70. Douglas A, Morris J. It was not just a heatwave! neuroleptic malignant-like syndrome in a patient with Parkinson's disease. Age Ageing 2006;35:640-1. (Pubitemid 44614165)
71. Newman EJ, Grosset DG, Kennedy PG. The Parkinsonism-hyperpyrexia syndrome. Neurocrit Care 2009;10:136-40.
72. Shalev A, Hermesh H, Munitz H. Mortality from neuroleptic malignant syndrome. J Clin Psychiatry 1989;50:18-25. (Pubitemid 19050611)
73. Galvez-Jiminez N, Lang AE. Perioperative problems in Parkinson's disease and their management: apomorphine with rectal domperidone. Can J Neurol Sci 1996;23:198-203. (Pubitemid 26302747)
74. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med 2005;352:1112-20.
75. Brodribb TR, Downey M, Gilbar PJ. Efficacy and adverse effects of moclobemide. Lancet 1994;343:475.
76. Benazzi F. Serotonin syndrome with moclobemide-fluoxetine combination. Pharmacopsychiatry 1996;29:162.
77. Richard IH, Kurlan R, Tanner C, et al. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Parkinson Study Group. Neurology 1997;48:1070-7.
78. Hinds NP, Hillier CM, Wiles CM. Possible serotonin syndrome arising from an interaction between nortriptyline and selegiline in a lady with Parkinsonism. J Neurol 2000;247:811.
79. Gillman PK. Possible serotonin syndrome with moclobemide and pethidine. Med J Aust 1995;162:554.
80. Menza MA, Robertson-Hoffman DE, Bonapace AS. Parkinson's disease and anxiety: comorbidity with depression. Biol Psych 1993;34:465-70. (Pubitemid 23337729)
81. Dooneef G, Mirabello E, Bell K, et al. An estimate of the incidence of depression in idiopathic Parkinson's disease. Arch Neurol 1992;49:305-7.
82. Graudins A, Stearman A, Chan B. Treatment of the serotonin syndrome with cyproheptadine. J Emerg Med 1998;16:615-19. (Pubitemid 28348173)
83. Dunkley EJ, Isbister GK, Sibbritt D, et al. The hunter serotonin toxicity criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM 2003;96:635-42. (Pubitemid 37063272)
84. Gillman PK. The serotonin syndrome and its treatment. J Psychopharmacol 1999;13:100-9. (Pubitemid 29141280)
85. Chan BS, Graudins A, Whyte IM, et al. Serotonin syndrome resulting from drug interactions. Med J Aust 1998;169:523-5. (Pubitemid 28519989)
86. Birmes P, Coppin D, Schmitt L, et al. Serotonin syndrome: a brief review. J Clin Psychopharmacol 1997;17:128-9.